KOD Latest Headlines

KOD Highlights GLOW2 Phase 3 Success: Zenkuda Shows 62.5% DRSS Improvement and 85% Risk Reduction in Diabetic Retinopathy

Market Chameleon (Fri, 27-Mar 10:30 AM)

Analysts’ Top Healthcare Picks: ARS Pharmaceuticals (SPRY), Kodiak Sciences (KOD)

at www.tipranks.com (Fri, 27-Mar 10:00 AM)

Kodiak Sciences’ Zenkuda Shows Strong Phase 3 GLOW2 Results

at www.tipranks.com (Fri, 27-Mar 8:18 AM)

Phase 3 Results Position Zenkuda as a Standout in Diabetic Retinopathy—85% Risk Reduction for Sight-Threatening Complications

Market Chameleon (Thu, 26-Mar 9:53 AM)

Kodiak’s Zenkuda Phase 3 Trial Achieves 62.5% Improvement Rate in Diabetic Retinopathy—Durable Benefits and Strong Safety Highlighted

Market Chameleon (Thu, 26-Mar 7:05 AM)

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Kodiak Sciences (KOD)

at www.tipranks.com (Thu, 26-Mar 2:20 PM)

Analysts Are Bullish on Top Healthcare Stocks: Dianthus Therapeutics (DNTH), Equillium (EQ)

at www.tipranks.com (Thu, 26-Mar 10:50 AM)

Biggest stock movers Thursday: OLPX, MARA, SMCI, and more

at seekingalpha.com (Thu, 26-Mar 10:23 AM)

Kodiak climbs on late-stage trial win for diabetic retinopathy therapy

at seekingalpha.com (Thu, 26-Mar 7:04 AM)